Piramal Healthcare trades higher on the bourses
The scrip is currently trading at Rs. 421.00, up by 0.19%
Piramal Healthcare is currently trading at Rs. 421.00, up by 0.80 points or 0.19% from its previous closing of Rs. 420.20 on the BSE.
The scrip opened at Rs. 423.00 and has touched a high and low of Rs. 423.00 and Rs. 419.05 respectively. So far 896 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 562.50 on 02-Apr-2012 and a 52 week low of Rs. 340.00 on 30-Nov-2011.
Last one week high and low of the scrip stood at Rs. 438.05 and Rs. 410.25 respectively. The current market cap of the company is Rs. 7251.96 crore.
The promoters holding in the company stood at 53.07% while Institutions and Non-Institutions held 26.49% and 20.44% respectively.
Piramal Healthcare will present its Phase I clinical trial data for its investigational new drug candidate P1446A-05 at the Annual Meeting of the American Society for Clinical Oncology (ASCO) being convened in Chicago from June 1-5, 2012. This year’s ASCO meeting will bring together more than 34,000 participants from around the world and will focus on the theme of collaborating to Conquer Cancer.
The two posters from Piramal Healthcare and participating investigators to be discussed on June 2, 2012, in the Developmental Therapeutics- Expiremental Therapeutics session, will report results of Phase I Clinical studies for P1446A-05 conducted in India and Canada, each investigating two different closing schedules.
P1446A-05 is a potent inhibitor of cyclin dependent kinases (Cdks) which are enzymes that regulate the cell cycle. Dysregulation of the cell cycle is often observed in human malignancies which derive malignant growth and unbalances the normal balance between cell division and death.
P1446A-05 will be the second molecule in Piramal’s oncology pipeline to enter Phase II trials. The first molecule P276 is in Phase II/III trials for multiple indications of cancer.
| Company Name | CMP |
|---|---|
| Bajaj Finance | 6893.10 |
| Shriram Finance | 2885.00 |
| Aditya Birla Capital | 187.20 |
| SBI Cards AndPayment | 693.40 |
| Mah & Mah Finl. Serv | 265.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
